Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.51 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Xylene SCHEMBL6281558 | 0.83 | TBXAS1 (0.68) | TBXAS1NAPRTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL27939457 | 0.82 | TBXAS1 (0.64) | TDP1L3MBTL1TBXAS1NAPRTCYP1A2 | |
| SCHEMBL15316696 | 0.81 | L3MBTL1 (1.00) | TDP1L3MBTL1ALDH1A1 | |
| SCHEMBL12530406 | 0.80 | TBXAS1 (0.57) | TDP1L3MBTL1TBXAS1NAPRTCYP1A2 | |
| SCHEMBL3373232 | 0.79 | TBXAS1 (0.55) | TDP1L3MBTL1TBXAS1NAPRTALDH1A1 | |
| SCHEMBL6888085 | 0.79 | ALDH1A1 (0.59) | TDP1L3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL21093385 | 0.78 | TDP1 (0.57) | TDP1L3MBTL1TBXAS1NAPRTCYP1A2 | |
| SCHEMBL9706562 | 0.77 | NAMPT (0.67) | TDP1ALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7280697 | 0.76 | NAPRT (0.61) | TDP1L3MBTL1TBXAS1NAPRTCYP1A2 | |
| SCHEMBL4200852 | 0.76 | TBXAS1 (0.57) | TBXAS1NAPRTCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273034-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | TDP1 3947/4885L3MBTL1 3563/4885TBXAS1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.